![]() |
Name |
Pestalotether D
|
Molecular Formula | C18H18O8 | |
IUPAC Name* |
methyl 2-hydroxy-6-(2-hydroxy-4-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoate
|
|
SMILES |
CC1=CC(=C(C(=C1)OC2=C(C=C(C=C2O)OC)C(=O)OC)C(=O)OC)O
|
|
InChI |
InChI=1S/C18H18O8/c1-9-5-12(19)15(18(22)25-4)14(6-9)26-16-11(17(21)24-3)7-10(23-2)8-13(16)20/h5-8,19-20H,1-4H3
|
|
InChIKey |
QVUUGDKCVIHHKR-UHFFFAOYSA-N
|
|
Synonyms |
Pestalotether D; NCGC00381149-01!methyl 2-hydroxy-6-(2-hydroxy-4-methoxy-6-methoxycarbonylphenoxy)-4-methylbenzoate
|
|
CAS | NA | |
PubChem CID | 44715302 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 362.3 | ALogp: | 3.3 |
HBD: | 2 | HBA: | 8 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 112.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 26 | QED Weighted: | 0.777 |
Caco-2 Permeability: | -4.912 | MDCK Permeability: | 0.00001960 |
Pgp-inhibitor: | 0.029 | Pgp-substrate: | 0.006 |
Human Intestinal Absorption (HIA): | 0.122 | 20% Bioavailability (F20%): | 0.009 |
30% Bioavailability (F30%): | 0.161 |
Blood-Brain-Barrier Penetration (BBB): | 0.126 | Plasma Protein Binding (PPB): | 96.89% |
Volume Distribution (VD): | 0.529 | Fu: | 7.39% |
CYP1A2-inhibitor: | 0.959 | CYP1A2-substrate: | 0.907 |
CYP2C19-inhibitor: | 0.927 | CYP2C19-substrate: | 0.134 |
CYP2C9-inhibitor: | 0.766 | CYP2C9-substrate: | 0.885 |
CYP2D6-inhibitor: | 0.595 | CYP2D6-substrate: | 0.654 |
CYP3A4-inhibitor: | 0.68 | CYP3A4-substrate: | 0.221 |
Clearance (CL): | 12.21 | Half-life (T1/2): | 0.833 |
hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.051 |
Drug-inuced Liver Injury (DILI): | 0.571 | AMES Toxicity: | 0.101 |
Rat Oral Acute Toxicity: | 0.284 | Maximum Recommended Daily Dose: | 0.765 |
Skin Sensitization: | 0.461 | Carcinogencity: | 0.016 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.907 |
Respiratory Toxicity: | 0.368 |